How Paterson was paid
$2.3M in total for 2025, as reported in the Summary Compensation Table. Equity awards are valued at grant, not at what they turned out to be worth.
Named executive officers
| Executive | Salary | Stock | Options | Incentive | Other | Total |
|---|---|---|---|---|---|---|
| Daniel PatersonPresident and Chief Executive Officer | $674,000 | $1,161,661 | — | $489,324 | $24,990 | $2,349,975 |
| Matthew RosFormer Chief Operating Officer | $455,154 | $585,330 | — | $196,425 | $388,254 | $1,625,163 |
| Daniel CalkinsChief Financial Officer | $350,000 | $450,721 | — | $151,200 | $24,950 | $976,871 |
| Michael Kauffman, M.D., Ph.D.President of Development | $30,000 | $62,331 | $75,662 | — | $105,000 | $272,993 |
What changed and why
- $2.3MDaniel Paterson received total compensation of $2,349,975 in fiscal year 2025 compared to $2,536,767 in fiscal year 2024.
- Verastem received FDA approval for the AVMAPKI FAKZYNJA CO-PACK in May 2025 for recurrent low-grade serous ovarian cancer.
- $30.9MThe CO-PACK generated net product revenues of $30.9 million for the full year 2025.
- Verastem transitioned from a clinical-stage company to a fully integrated biopharmaceutical company during 2025.
About this page
Figures are automated and can be wrong; check the filing for the exact numbers. Totals follow SEC rules, which value stock and option awards at grant. Read the DEF 14A proxy statement for footnotes and the compensation committee's full reasoning.